MedTrace Logo

Effect of Anti-interleukin 5 (IL5) Therapy on Sputum Cells and Cytokines

NCT04412044 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 22

Last updated 2020-06-02

No results posted yet for this study

Summary

22 asthmatics, in which mepolizumab was to be started, gave permission for inclusion and were followed up prospectively. Clinical and lung functional data, sputum analyses and cytokine measurements were analyzed.

Conditions

Interventions

DRUG

Mepolizumab Injection [Nucala]

Patients receive monthly injection with 100 mg mepolizumab

Sponsors & Collaborators

  • KU Leuven

    lead OTHER

Principal Investigators

  • Tatjana Decaesteker · KU Leuven

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2016-09-01
Primary Completion
2018-05-01
Completion
2019-03-01
FDA Drug
Yes

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04412044 on ClinicalTrials.gov